Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year ...

Live Updates Live Coverage Updates appear automatically as they are published. Moderna Still Sickly 9:49 am In further ...

Moderna reduced its 2025 revenue forecast due to deferred UK vaccine deliveries. Despite a smaller-than-expected quarterly loss, its shares fell 7%. The company faces challenges from declining ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Circular RNA may be part of the solution. Because circular RNA has no ends to degrade—unlike linear RNA—the molecule is more stable and its half-life is extended.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a ...

Today, Benzinga 's options scanner spotted 17 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 52% bullish and 35%, bearish.